Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05086146
Other study ID # 2020-63
Secondary ID 2020-A03384-35
Status Recruiting
Phase
First received
Last updated
Start date August 10, 2021
Est. completion date March 2024

Study information

Verified date October 2021
Source Assistance Publique Hopitaux De Marseille
Contact DEHARO PIERRE
Phone (0)4 91 96 86 83
Email pierre.deharo@ap-hm.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

It consists of evaluating the advantage of routine detection of phIGFBP-1 to reduce the total duration of hospitalization for patients with a risk of preterm labor before 32 weeks of gestation without increasing the number of preterm labour.


Description:

Patient with a risk of preterm labor (ultrasound cervical length < 25 mm +/- described or recorded uterine contractions) before 32 weeks of gestation will be hospitalized to receive tocolytic drugs and antenatal corticosteroid therapy according to the investigators gold standard protocol. After 48 hours, the participants will be assessed by examination, external tocodynamometry and the measure of cervical length by ultrasound. Stabilized patients will be included and randomized into 2 groups of 210 patients each. The first group "A" will benefit from the standard protocol (extended hospitalization of 2 or 4 days according to the clinical and ultrasound assessment); whereas the second group, "B", will have the benefit of the detection of phIGFBP-1.If the result proves negative, patients could be discharged early at day 2. In the case of a positive result, patients will follow the standard procedure because of the low positive predictive value of the test. The main outcome is the total duration of hospitalization.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date March 2024
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: All patients affiliated to the French social security system will be eligible, after signing a consent form, and presenting the following criteria - Introduction within the last 3 months of at least one of the following ICIs: nivolumab, pembrolizumab, cemiplimab, avelumab, atezolizumab, ipilimumab, tremelimumab, durvalumab. - Suspicion of myocarditis defined by the presence of at least one of the following criteria adapted from the European Society of Cardiology guidelines: - Symptomatic patients (chest pain, dyspnea, palpitations, syncope/lipothymia) within 7 days of ICI administration - New ECG abnormality (ST-segment elevation, ST-segment undershift, arrhythmia, conductive disturbances, T-wave inversion) - Elevation of troponin above the 99th percentile of the laboratory reference value or, if troponin is already elevated before treatment, an increase of more than 30% of the baseline value - Recent LVEF decline or recent LV contraction abnormality on a TTE - Patient has given no objection Translated with www.DeepL.com/Translator (free version) Exclusion Criteria: - Age <18 years - Major under guardianship or curatorship - Pregnant or breastfeeding women - Patient not covered by a social security plan - Hemodynamic or rhythmic instability - Estimation of glomerular filtration rate by the MDRD formula <30ml/min/1.73m2 - Implantable equipment that does not allow for cMRI

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France assistance publique hôpitaux de Marseille Marseille

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique Hopitaux De Marseille

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative incidence rate of the composite end point including cardiovascular death, acute heart failure, cardiogenic shock, cardiac arrest, sustained ventricular tachycardia, ventricular fibrillation, 2nd-degree (except Mobitz 1) or 3rd-degree atrioventricular block. 6-month
Secondary Cumulative incidence rate of all-cause death 6-month
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05911386 - Multiparametric Echocardiography and Cardiac Biomarkers in Pediatric Inflammatory Heart Diseases
Not yet recruiting NCT04085718 - FDG-PET/CT Images Comparing to MRI and Endomyocardial Biopsy in Myocarditis
Enrolling by invitation NCT05610423 - Covid-19 Vaccine Associated Myocarditis and Pericarditis in Norway
Active, not recruiting NCT05195645 - AbataCept for the Treatment of Immune-cHeckpoint Inhibitors Induced mYocarditiS Phase 2
Recruiting NCT05184114 - Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance N/A
Recruiting NCT04612296 - The Heart Hive - Cardiomyopathy Study
Recruiting NCT04673409 - CMR Imaging of Autoimmune Diseases
Recruiting NCT05295290 - A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. Phase 4
Completed NCT03777839 - PET-FDG in Myocarditis
Completed NCT06447935 - Acute Eosinophilic Myocarditis International Registry
Not yet recruiting NCT05125965 - Contribution of Cardiac MRI in the Early Diagnosis of Myocarditis Induced by Immunotherapy N/A
Active, not recruiting NCT04444128 - IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
Recruiting NCT06158698 - CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine Phase 3
Recruiting NCT05288426 - Myocarditis Post Vaccination or Multi System Inflammatory Syndrome
Recruiting NCT05282498 - Pathophysiologic Mechanism for MYOcarditis in COVID19 VAccinations ("MYOVAx" Study)
Recruiting NCT03801681 - ARrhythmias in MYocarditis
Recruiting NCT06116084 - Randomized Controlled Study Evaluating the Efficacy of Hypnosis in Nuclear Medicine N/A
Completed NCT04413071 - Cardiac COVID-19 Health Care Workers
Recruiting NCT05414162 - Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
Recruiting NCT06409585 - Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition